… mutation, using the cobas EGFR Mutation Test v2 at the time of progression on or after
first-line first- or second-generation EGFR-… to determine the frequency of EGFR T790M-mediated …

… for noninvasive evaluation. This prospective trial evaluated CTCs and cfDNA in EGFR-mutant …
Experimental Design: EGFR-mutant NSCLC patients were enrolled in a phase II trial of …

… the use of EGFR tyrosine kinase inhibition (TKI) as a first line treatment of choice for advanced
adenocarcinoma of the lung carrying an activating EGFR mutation. The mutation rate in …

… sarcoma (KRAS) mutation status, although associated with EGFR- tyrosine kinase inhibitor
(… The prospective Evaluation of the EGFR Mutation status for the administration of EGFR-TKIs …

… We identified all patients with metastatic EGFR exon19del or L858R-mutant lung cancers …
In this analysis, we evaluated the utility of TMB as a predictive biomarker in EGFR-mutant lung …

… It is imperative to rigorously and prospectively evaluate such strategies vis‐à‐vis emerging
data for EGFR‐T790M active and central nervous system–penetrant osimertinib (phase II trial …

… was to evaluate the usefulness of EGFR mutation status in … EGFR mutation status was
determined by a direct sequencing method and by Scorpion Amplification Refractory Mutation …

… EGFR mutations in plasma and outcomes was also a secondary end point. Tissue EGFR
mutation … by central testing if feasible using the cobas 4800 EGFR tissue test (Roche). Baseline …

… (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free …
a prospective analysis of the relationship between the mutational status of EGFR in plasma …

… either of these two hotspot mutations. Therefore, we developed a … mutations 29 and conducted
a prospective cohort study to explore the prediction of gefitinib sensitivity in EGFR mutation…